Suppr超能文献

相似文献

1
Structural Basis of CD160:HVEM Recognition.
Structure. 2019 Aug 6;27(8):1286-1295.e4. doi: 10.1016/j.str.2019.05.010. Epub 2019 Jun 20.
3
Redesigning HVEM Interface for Selective Binding to LIGHT, BTLA, and CD160.
Structure. 2020 Nov 3;28(11):1197-1205.e2. doi: 10.1016/j.str.2020.07.013. Epub 2020 Aug 13.
4
A herpesvirus entry mediator mutein with selective agonist action for the inhibitory receptor B and T lymphocyte attenuator.
J Biol Chem. 2017 Dec 22;292(51):21060-21070. doi: 10.1074/jbc.M117.813295. Epub 2017 Oct 23.
5
HVEM structures and mutants reveal distinct functions of binding to LIGHT and BTLA/CD160.
J Exp Med. 2021 Dec 6;218(12). doi: 10.1084/jem.20211112. Epub 2021 Oct 28.
6
CD160 isoforms and regulation of CD4 and CD8 T-cell responses.
J Transl Med. 2014 Sep 2;12:217. doi: 10.1186/s12967-014-0217-y.
7
The CD160, BTLA, LIGHT/HVEM pathway: a bidirectional switch regulating T-cell activation.
Immunol Rev. 2009 May;229(1):244-58. doi: 10.1111/j.1600-065X.2009.00783.x.
8
CD160 activation by herpesvirus entry mediator augments inflammatory cytokine production and cytolytic function by NK cells.
J Immunol. 2013 Jul 15;191(2):828-36. doi: 10.4049/jimmunol.1300894. Epub 2013 Jun 12.
9
BTLA inhibition has a dominant role in the -complex of BTLA and HVEM.
Front Immunol. 2022 Aug 23;13:956694. doi: 10.3389/fimmu.2022.956694. eCollection 2022.
10
CD160 inhibits activation of human CD4+ T cells through interaction with herpesvirus entry mediator.
Nat Immunol. 2008 Feb;9(2):176-85. doi: 10.1038/ni1554. Epub 2008 Jan 13.

引用本文的文献

2
Proteomic Investigation of Immune Checkpoints and Some of Their Inhibitors.
Int J Mol Sci. 2024 Aug 27;25(17):9276. doi: 10.3390/ijms25179276.
3
Effect of Variations on the Clear Cell Renal Carcinoma Risk and Overall Survival.
Int J Mol Sci. 2024 Jun 22;25(13):6860. doi: 10.3390/ijms25136860.
4
The role of the BTLA-HVEM complex in the pathogenesis of breast cancer.
Breast Cancer. 2024 May;31(3):358-370. doi: 10.1007/s12282-024-01557-7. Epub 2024 Mar 14.
5
T cell co-stimulatory and co-inhibitory pathways in atopic dermatitis.
Front Immunol. 2023 Mar 13;14:1081999. doi: 10.3389/fimmu.2023.1081999. eCollection 2023.
6
Transcriptional reprogramming of natural killer cells by vaccinia virus shows both distinct and conserved features with mCMV.
Front Immunol. 2023 Feb 23;14:1093381. doi: 10.3389/fimmu.2023.1093381. eCollection 2023.
7
CD160 receptor in CLL: Current state and future avenues.
Front Immunol. 2022 Nov 7;13:1028013. doi: 10.3389/fimmu.2022.1028013. eCollection 2022.
8
Human immunomodulatory ligand B7-1 mediates synaptic remodeling via the p75 neurotrophin receptor.
J Clin Invest. 2022 Nov 15;132(22):e157002. doi: 10.1172/JCI157002.

本文引用的文献

1
Complex Interplay between Epitope Specificity and Isotype Dictates the Biological Activity of Anti-human CD40 Antibodies.
Cancer Cell. 2018 Apr 9;33(4):664-675.e4. doi: 10.1016/j.ccell.2018.02.009. Epub 2018 Mar 22.
2
A herpesvirus entry mediator mutein with selective agonist action for the inhibitory receptor B and T lymphocyte attenuator.
J Biol Chem. 2017 Dec 22;292(51):21060-21070. doi: 10.1074/jbc.M117.813295. Epub 2017 Oct 23.
3
HVEM Imprints Memory Potential on Effector CD8 T Cells Required for Protective Mucosal Immunity.
J Immunol. 2017 Oct 15;199(8):2968-2975. doi: 10.4049/jimmunol.1700959. Epub 2017 Sep 1.
4
Crystal Structure of the Complex of Human FasL and Its Decoy Receptor DcR3.
Structure. 2016 Nov 1;24(11):2016-2023. doi: 10.1016/j.str.2016.09.009.
5
Processing of X-ray diffraction data collected in oscillation mode.
Methods Enzymol. 1997;276:307-26. doi: 10.1016/S0076-6879(97)76066-X.
6
Loss of the HVEM Tumor Suppressor in Lymphoma and Restoration by Modified CAR-T Cells.
Cell. 2016 Oct 6;167(2):405-418.e13. doi: 10.1016/j.cell.2016.08.032. Epub 2016 Sep 29.
8
The TNF Receptor Superfamily in Co-stimulating and Co-inhibitory Responses.
Immunity. 2016 May 17;44(5):1005-19. doi: 10.1016/j.immuni.2016.04.019.
9
Neuron-specific SALM5 limits inflammation in the CNS via its interaction with HVEM.
Sci Adv. 2016 Apr 8;2(4):e1500637. doi: 10.1126/sciadv.1500637. eCollection 2016 Apr.
10
Facilitating T Cell Infiltration in Tumor Microenvironment Overcomes Resistance to PD-L1 Blockade.
Cancer Cell. 2016 Mar 14;29(3):285-296. doi: 10.1016/j.ccell.2016.02.004.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验